Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Tuesday 9 June at 4:30pm because of system upgrades. We expect to open them again on Wednesday 10 June at 8am the latest.

E!9168, 3DPERLAT, Karolinska Institutet

Reference number
Coordinator Karolinska Institutet - Karolinska Institutet Inst f fysiologi & farmakologi
Funding from Vinnova SEK 1 890 000
Project duration April 2026 - March 2028
Status Ongoing
Venture Eurostars

Purpose and goal

The aim of this project is to develop and validate a human-relevant in vitro model for studying adipose tissue in obesity. Through 3D bioprinting, biomaterials and microfluidic perfusion, a vascularized, perfused adipose tissue model is created that mimics the human microenvironment. The goal is to establish a robust platform for studying metabolism, inflammation and drug response of human fat tissue.

Expected effects and result

The project is expected to result in a validated, vascularized and perfused 3D model of human adipose tissue with high physiological relevance. The platform will enable long-term culture and analysis of metabolic and inflammatory processes and drug effects. The model improves the understanding of obesity and its mechanisms and strengthens preclinical drug development through more accurate, human-relevant testing platforms.

Planned approach and implementation

The project is implemented in four steps: (1) biomaterial development and design, (2) 3D bioprinting of vascularized adipose tissue, (3) integration into a perfusion bioreactor, and (4) functional validation and drug testing. The work is carried out in close collaboration between partners using iterative optimization and standardized analyses.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 7 April 2026

Reference number 2026-00055